Danaher Beats Q2 Estimates, Raises Full-Year EPS Guidance to $8.45-$8.60
DHR is trading near its 52-week low of $160.93 (14% above the low).
Summary
Danaher delivered a strong Q2 beat with revenue of $6.27B and adjusted EPS of $1.94, topping consensus by $170M and $0.11 respectively. The Life Sciences segment posted its best quarter in years, while bioprocessing orders grew mid-teens despite revenue timing headwinds. Management raised full-year adjusted EPS guidance to $8.45-$8.60 and expects 3%-4% core revenue growth, reflecting confidence from the earlier-than-expected Masimo acquisition close. This follows the 10-Q filed yesterday and adds concrete quarterly numbers and raised annual targets. The stock trades at 23x forward earnings with a median analyst target of $237.50, suggesting room to run if execution continues.
At the time of this announcement, DHR was trading at $184.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $142.3B. The 52-week trading range was $160.93 to $242.80. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.